|Slideshows|December 13, 2022

The Year in Schizophrenia Research

Psychiatric Times looks back on the major research on schizophrenia from 2022.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Long-Acting Injectables in Schizophrenia: Closing the Gap Between Evidence and Practice

ByHeidi Anne Duerr, MPH

July 11th 2026

Building Trust in Schizophrenia Care: How the Therapeutic Alliance Shapes Outcomes

ByGerald A. Maguire, MD

July 11th 2026

Phase 2 Trial Initiated for Briumvi for Treatment-Resistant Schizophrenia

ByJessica Walters

July 6th 2026

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

BySusan Hatters Friedman, MD, MSt, DFAPA,Ashley A. Mulvihill, MD

June 25th 2026

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

ByAntonio Vita, MD, PhD,Gabriele Nibbio, MD, PhD,Stefano Barlati, MD

June 19th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

The Year in Schizophrenia Research

Related Content

Long-Acting Injectables in Schizophrenia: Closing the Gap Between Evidence and Practice

Building Trust in Schizophrenia Care: How the Therapeutic Alliance Shapes Outcomes

Phase 2 Trial Initiated for Briumvi for Treatment-Resistant Schizophrenia

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Psychedelics, Orexin Blockers, and More: Inside the Diverse New Pipeline for Depression

New 6-Month Data From Second Phase 3 Trial Confirms Rapid Effect of COMP360 for TRD

Long-Acting Injectables in Schizophrenia: Closing the Gap Between Evidence and Practice

COMP360 Psilocybin in Treatment-Resistant Depression: Insights From Gus Alva, MD, DFAPA

Expanding ADHD Pharmacology: Pipeline Highlights With Ann Childress, MD